Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | IL1RN | P18510 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | RECQL | P46063 | 1/20 | 0.75 |
| ▸ | APEX1 | P27695 | 1/20 | 0.68 |
| ▸ | ALB | P02768 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30005696 | 1.00 | MAPT (0.76) | MAPTIL1RNTSHRRECQLAPEX1 | |
| SCHEMBL28283475 | 0.90 | TSHR (0.77) | TSHRRECQLMAPK1NPC1GAA | |
| SCHEMBL15773014 | 0.87 | TSHR (0.73) | TSHRRECQLMAPK1NPC1GAA | |
| SCHEMBL7321050 | 0.87 | KMT2A (0.80) | MAPTTSHRRECQLMAPK1ALDH1A1 | |
| SCHEMBL2850336 | 0.87 | GAA (0.74) | TSHRRECQLMAPK1NPC1GAA | |
| SCHEMBL3932198 | 0.86 | MAPT (0.94) | MAPTIL1RNTSHRAPEX1NPC1 | |
| SCHEMBL29463849 | 0.86 | MAPT (1.00) | MAPTIL1RNTSHRAPEX1NPC1 | |
| SCHEMBL1001486 | 0.86 | MAPT (1.00) | MAPTIL1RNTSHRAPEX1NPC1 | |
| SCHEMBL1001537 | 0.85 | MAPT (0.97) | MAPTIL1RNTSHRAPEX1NPC1 | |
| SCHEMBL30213397 | 0.85 | MAPT (0.97) | MAPTIL1RNTSHRAPEX1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| EP-3551634-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | claimed |
| CN-110099905-A | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-06 | — | — | CN | claimed |
| CN-110088108-A | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-02 | — | — | CN | claimed |
| WO-2018108231-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | claimed |
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| US-4029787-A | Basically substituted 3-sulfamoylbenzoic acid derivatives and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-06-14 | — | — | US | claimed |
| EP-4737451-A1 | NOVEL CARBOXAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025003988-A1 | NOVEL CARBOXAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 동화약품주식회사 | 2025-01-02 | — | — | WO | disclosed |
| US-20240018242-A1 | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY | CHILDREN'S MEDICAL CENTER CORPORATION | 2024-01-18 | — | — | US | disclosed |
| EP-4219689-A2 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| US-11685782-B2 | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-06-27 | — | — | US | disclosed |
| EP-3397756-B1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018414-A2 | ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004007498-A2 | 3-PHENYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-22 | — | — | WO | disclosed |
| US-20020111369-A1 | Aryl sulfonic acids and derivatives as FSH antagonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-08-15 | — | — | US | disclosed |
| US-6355633-B1 | CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-12 | — | — | US | disclosed |
| WO-2000058277-A1 | ARYL SULFONIC ACIDS AND DERIVATIVES AS FSH ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685782-B2 | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy | KDM1B, KDM2A, KDM3B | MAPT 3200/4885IL1RN 1104/4885TSHR 4077/4885 |
| US-20020111369-A1 | Aryl sulfonic acids and derivatives as FSH antagonists | FSHR, GNRHR, LHCGR | MAPT 4858/4885IL1RN 1414/4885TSHR 29/4885 |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | MAPT 4754/4885IL1RN 790/4885TSHR 3901/4885 |
| US-20240018242-A1 | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY | KDM1B, KDM2A, KDM3B | MAPT 3200/4885IL1RN 1104/4885TSHR 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.